# OnCo record mantle-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mantle-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mantle-cell-lymphoma" ;
  schema:name "Mantle cell lymphoma"@en ;
  schema:description "An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."@en ;
  schema:url <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mantle_cell_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q268713> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)00184-3>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480>, <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/waldenstrom/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/clonoseq/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/mipi/>, <https://onco.cc/terms/cyclin-d1-t11-14/> ;
  onco:trials <https://onco.cc/trials/nct07377578/>, <https://onco.cc/trials/nct04002297/>, <https://onco.cc/trials/nct01804686/>, <https://onco.cc/trials/nct06742996/>, <https://onco.cc/trials/nct06363994/>, <https://onco.cc/trials/nct04662255/>, <https://onco.cc/trials/nct02972840/>, <https://onco.cc/trials/zuma-2/> ;
  onco:pipeline <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/bgb-16673/>, <https://onco.cc/drugs/nemtabrutinib/>, <https://onco.cc/drugs/rocbrutinib/>, <https://onco.cc/drugs/icp-248/>, <https://onco.cc/drugs/zamtocabtagene-autoleucel/>, <https://onco.cc/drugs/ctx112/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/trials/triangle/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/sympatico/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/technologies/allogeneic-hsct/> .